Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PETRI

Financiado

Cerrado

Phages against MDR Enterococcus faecium

Due to its multidrug resistance (MDR), Enterococcus faecium (Efm) poses a challenge to the healthcare system and renders most standard antibiotics useless. Bacteriophage (phage) therapy has resurfaced as a treatment strategy for... ver más

31/08/2028

NORSK POLARINSTITU...

308K€

Presupuesto del proyecto: 308K€

Líder del proyecto

NORSK POLARINSTITUTT No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-04-23

HORIZON-MSCA-2023-PF-01-01: MSCA Postdoctoral Fellowships 2023 ExpectedOutcome:Project results are expected to contribute to the following outcomes:

I+D

Cerrada hace 1 año

0% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

NORSK POLARINSTITUTT

307.94K€ | Lider

REGENTS OF THE UNIVERSITY OF...

UCD

N.D. | Participante

Proyectos interesantes

CNS2023-144312

Medical Technol...

Data Science

200K€ Cerrado

ECOSTRAT

Medical Technol...

Data Science

2M€ Cerrado

COMBACTE-MAGNET

Medical Technol...

Data Science

169M€ Cerrado

SAF2014-56568-R

Medical Technol...

Data Science

Cerrado

BFU2016-77835-R

Medical Technol...

Data Science

121K€ Cerrado

COMBACTE-CARE

Medical Technol...

Data Science

85M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 52 meses Fecha Inicio: 2024-04-23
Fecha Fin: 2028-08-31

Líder del proyecto

NORSK POLARINSTITUTT No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 308K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Due to its multidrug resistance (MDR), Enterococcus faecium (Efm) poses a challenge to the healthcare system and renders most standard antibiotics useless. Bacteriophage (phage) therapy has resurfaced as a treatment strategy for bacterial infections due to increasing antibiotic resistance. Its advantages include specificity, low side effects and production costs, especially when used in combination with standard-of-care antibiotics. Phage therapy has been successful in compassionate use, but its wider implementation is hindered by a lack of knowledge on which antibiotics phages synergize and the mechanisms behind remain elusive. Our project is unique in that it aims to enable the use of conventional antibiotics in MDR Efm through phages. We want to explore which antibiotic classes phages synergize with, which survival strategies Efm uses against phages, and how host factors influence the ability of the antibiotic-phage combination to kill Efm. First, we will investigate phages' interaction with different antibiotic classes against Efm. We will explore the dynamics of phage-antibiotic combinations and whether they are additive, synergistic, or antagonistic. Second, potential phage survival strategies of Efm will be investigated. Additionally, membrane vesicles will be investigated as a potential survival strategy against phages, and their ability to act as a decoy and protect the bacterium from phages will be studied. Third, we will investigate the impact of host factors on the phage-antibiotic killing of Efm, to see whether they can enhance or suppress the phage-antibiotic killing. This approach will provide a deeper understanding of the phages-antibiotic interaction against MDR Efm strains, as well as potential survival systems of Efm which may also shed light on possible mitigation strategies. Overall, this approach has the potential to enable the use of standard-of-care drugs against MDR bacterial infections in general.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores